SCHEMBL4481569

SCHEMBL4481569

N#CCC(=O)NC(=O)c1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MCL1 Q07820 1/20 0.54
GAA P10253 4/20 0.50
THRB P10828 1/20 0.50
ALDH1A1 P00352 7/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
TP53 P04637 1/20 0.46
MEN1 O00255 1/20 0.46
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46
KMT2A Q03164 1/20 0.46
KDM4E B2RXH2 1/20 0.46
HSD17B10 Q99714 2/20 0.45
HDAC3 O15379 1/20 0.45
CA12 O43570 1/20 0.45
CA1 P00915 1/20 0.45
IDO1 P14902 1/20 0.45
ALOX15 P16050 1/20 0.45
HDAC1 Q13547 1/20 0.45
CA9 Q16790 1/20 0.45
HDAC7 Q8WUI4 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4471126 0.76 MCL1 (0.62) MCL1GAAALDH1A1MEN1KMT2A
Benzoic Acid Hydrazide SCHEMBL11335640 0.76 ALDH1A1 (0.46) MCL1GAAALDH1A1NPC1RAB9A
SCHEMBL4480718 0.76 HDAC6 (0.51) MCL1GAATHRBALDH1A1SMN1; SMN2
SCHEMBL2710556 0.75 SMN1; SMN2 (0.53) MCL1GAAALDH1A1SMN1; SMN2TP53
SCHEMBL15660833 0.75 MCL1 (0.60) MCL1ALDH1A1SMN1; SMN2MEN1RAB9A
SCHEMBL76489 0.75 ALDH1A1 (0.67) GAAALDH1A1SMN1; SMN2TP53MEN1
SCHEMBL8799020 0.75 SMN1; SMN2 (0.64) GAAALDH1A1SMN1; SMN2TP53MEN1
SCHEMBL3363210 0.75 ALDH1A1 (0.67) GAAALDH1A1SMN1; SMN2TP53MEN1
SCHEMBL7699974 0.75 ALDH1A1 (0.57) GAAALDH1A1SMN1; SMN2TP53MEN1
SCHEMBL3627085 0.75 ALDH1A1 (0.55) GAAALDH1A1SMN1; SMN2TP53MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7598419-B2 Compounds for modulating cell proliferation HSC RESEARCH AND DEVELOPMENT LIMITED PARTNERSHIP (CA) 2009-10-06 US disclosed
US-20070243612-A1 Novel Compounds for Modulating Cell Proliferation HSC RESEARCH AND DEVELOPMENT LIMITED PARTNERSHIP (CA) 2007-10-18 US disclosed
EP-1727822-A4 NOVEL COMPOUNDS FOR MODULATING CELL PROLIFERATION HSC RES DEV LP (CA) 2007-05-09 EP disclosed
EP-1752446-A2 Compounds for modulating cell proliferation HSC Research and Development Limited Partnership (CA) 2007-02-14 EP disclosed
WO-2007006143-A1 COMPOSITIONS AND METHODS FOR DETECTING TRANSFORMED CELLS THE HOSPITAL FOR SICK CHILDREN (CA) 2007-01-18 WO disclosed
EP-1272457-B9 COMPOUNDS FOR MODULATING CELL PROLIFERATION HSC RES DEV LP (CA) 2006-12-20 EP disclosed
EP-1727822-A1 NOVEL COMPOUNDS FOR MODULATING CELL PROLIFERATION HSC Research and Development Limited Partnership (CA) 2006-12-06 EP disclosed
US-20060241084-A1 Inhibition of vascular endothelial growth factor THE HOSPITAL FOR SICK CHILDREN (CA) 2006-10-26 US disclosed
EP-1272457-B1 COMPOUNDS FOR MODULATING CELL PROLIFERATION HSC RES DEV LP (CA) 2006-08-23 EP disclosed
EP-1638912-A2 PROCESS FOR THE PREPARATION OF CINNAMALDEHYDE COMPOUNDS Lymphosign Inc. (CA) 2006-03-29 EP disclosed
WO-2004032911-A2 STYRYLACRYLONITRILE COMPOUNDS FOR INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR THE HOSPITAL FOR SICK CHILDREN (CA) 2004-04-22 WO disclosed
US-20040072803-A1 Novel compounds for modulating cell proliferation HSC RESEARCH AND DEVELOPMENT LIMITED (CA) 2004-04-15 US disclosed
EP-1047695-B1 NOVEL BISPIDINE ANTIARRHYTHMIC COMPOUNDS ASTRAZENECA AB (SE) 2004-03-17 EP disclosed
US-20030109502-A1 Novel compounds for modulating cell proliferation HSC RESEARCH AND DEVELOPMENT LIMITED PARTNERSHIP (CA) 2003-06-12 US disclosed
WO-2003030895-A1 STYRYL ACRYLONITRILE COMPOUNDS AND THEIR USE TO PROMOTE MYELOPOIESIS THE HOSPITAL FOR SICK CHILDREN (CA) 2003-04-17 WO disclosed
EP-1272457-A2 COMPOUNDS FOR MODULATING CELL PROLIFERATION HSC Research and Development Limited Partnership (CA) 2003-01-08 EP disclosed
WO-2001079158-A2 COMPOUNDS FOR MODULATING CELL PROLIFERATION HSC RESEARCH AND DEVELOPMENT LIMITED PARTNERSHIP (CA) 2001-10-25 WO disclosed
US-6291475-B1 3,7-DIAZABICYCLO(3.3.1)NONANE DERIVATIVES ASTRAZENECA AB (SE) 2001-09-18 US disclosed
EP-1047695-A1 NOVEL BISPIDINE ANTIARRHYTHMIC COMPOUNDS AstraZeneca AB (SE) 2000-11-02 EP disclosed
WO-1999031100-A1 NOVEL BISPIDINE ANTIARRHYTHMIC COMPOUNDS ASTRAZENECA AB (SE) 1999-06-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060241084-A1 Inhibition of vascular endothelial growth factor VEGFA, FLT4, FLT1 MCL1 1303/4885GAA 1635/4885THRB 1501/4885
US-20070243612-A1 Novel Compounds for Modulating Cell Proliferation MKI67, CCNA1, PCNA MCL1 7/4885GAA 3161/4885THRB 2167/4885
US-20030109502-A1 Novel compounds for modulating cell proliferation MKI67, CCNA1, CCNI MCL1 5/4885GAA 3148/4885THRB 1809/4885
US-20040072803-A1 Novel compounds for modulating cell proliferation MKI67, CCNA1, MCL1 MCL1 3/4885GAA 3256/4885THRB 1825/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.